Edap Tms SA

Edap Tms SA(FOCL)の株式分析

$4.340

+0.243 (+5.60%)終値時点

Loading chart…
高値
4.400
始値
4.240
出来高加重平均価格
4.33
出来高
7.93K
時価総額
—
安値
4.240
売買代金
34.31K
EV/EBITDA(TTM)
-5.24

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

AI分析 of Edap Tms SA (FOCL)

買い

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

バリュエーション指標

Edap Tms SA(FOCL)の現在の予想PERは38.91で、5年平均は38.91です。

予想PER

適正
5年平均 P/E
38.91
現在のP/E
38.91
割高
38.91
割安
38.91

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-6.00
現在のEV/EBITDA
-5.24
割高
-4.78
割安
-7.22

予想PSR

適正
5年平均 P/S
2.79
現在のP/S
2.78
割高
3.04
割安
2.54

FOCL を保有するクジラ

S

Soleus Capital Management, L.P.

+ を保有FOCL

-7.34%

3か月リターン

イベントタイムライン

2026-08-14 (ET)

12:00:00

Major Averages Broadly Lower Near Noon

2026-08-13 (ET)

16:30:00

Company Announces ESWL and Distribution Segments as Discontinued Operations

16:30:00

FocalTherics Q2 Revenue at $13.2M, Below Expectations

2026-08-11 (ET)

21:30:00

TD Cowen and Mizuho Jointly Manage Offering

17:00:00

Sees Q2 Gross Margin at 54%-56%

ニュース

FOCL のよくある質問 — Alphio AI が回答

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector.

Edap Tms SA (FOCL) appears to be a good buy right now, trading at $4.34 with a strong RSI of 62.29 indicating bullish momentum. The company's gross margin has improved significantly to 55.58%, up from 42.52% in the previous year, showcasing operational efficiency. Additionally, analysts have set a price target of $15 from Mizuho, suggesting a potential upside of over 245% from the current price. However, the main risk is the negative earnings per share forecast of -0.18 for the next earnings report, which could impact investor sentiment.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める